Dan Mahony

Dan Mahony is a prominent figure in the life sciences and investment sectors with extensive experience in healthcare and biotechnology. He served as Entrepreneur-in-Residence at Evotec (UK) Limited from October 2021 to February 2023.12

Career Highlights

Investment Expertise:: Prior to his role at Evotec, Mahony was Co-Head of Healthcare at Polar Capital, where he launched the healthcare business in 2007 and grew it to over $4 billion in assets under management.1 He has over 25 years of experience in global healthcare, covering biotechnology, medical technology, and healthcare services.1

Research Background:: Mahony's career includes positions as head of European healthcare research at Morgan Stanley, an analyst at ING Barings Furman Selz in New York, and a research scientist at Schering Plough.1

Current Roles

• Senior Partner at Novo Growth Investments, Novo Holdings (as of 2024)25
• Chair of the board of the BioIndustry Association (BIA), the industry trade association for UK life sciences1

Other Positions

Mahony holds several non-executive directorships, including:

• Wellcome Sanger Institute
• Trellus Health (LSE-listed digital health company)
• Celmatix (preclinical-stage women's health biotech)
• Keepabl (SaaS provider for GDPR compliance)
• Apian (healthcare drone startup)
• Sernova (biotech company)4

He also serves as a mentor for the NHS Clinical Entrepreneur Training Programme.1

Recent Appointment

In November 2022, Dr. Dan Mahony was appointed as the UK Government's Life Sciences Investment Envoy by the Secretary of State for Business, Energy and Industrial Strategy.13 In this role, he champions the UK life sciences sector to national and international investors to help increase investment in scaling life science companies.1